Gilead To Test Inhaled Version Of Remdesivir
GILEAD SCIENCES HAS ANNOUNCED PLANS TO TEST INHALED VERSION OF REMDESIVIR AS POTENTIAL COVID-19 TREATMENT
(CNN) – The company that makes the antiviral drug Remdesivir is about to test an inhaled version of the medication as potential COVID-19 treatment.
Remdesivir is the only drug right now that has emergency-use FDA approval to treat COVID-19 infections.
The medication is currently administered through daily IV infusions at a hospital, but Gilead Sciences announced on Monday the FDA has given the company the green light to start trials of an inhaled version of Remdesivir.
Gilead chairman and CEO said they “will screen healthy volunteers for phase one trials this week and hope to begin studies in patients with COVID-19 in August.”